Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model

Egyptian Liver Journal

Table 7 Classifying Child A cases into low- and high-risk groups for TACE according to the AFP model

		Child A		Test value	P value	Sig.
		Low-risk	High-risk
		No. = 52	No. = 67
Response	Complete response	48 (92.3%)	49 (73.1%)	7.799*	0.050	NS
	Partial response	4 (7.7%)	14 (20.9%)
	Stationary disease	0 (0.0%)	2 (3.0%)
	Progressive disease	0 (0.0%)	2 (3.0%)
Recurrence	No recurrence	15 (31.2%)	11 (22.4%)	0.957*	0.328	NS
Recurrence	Recurrence	33 (68.8%)	38 (77.6%)	0.957*	0.328	NS
Recurrence-free survival	Median (IQR)	13 (6–18)	6 (3–16)	− 2.198≠	0.028	S
Recurrence-free survival	Range	3–36	3–30	− 2.198≠	0.028	S
OS (months)	Median (IQR)	18.5 (15.5–24.5)	16 (10–20)	− 3.713≠	0.000	HS
OS (months)	Range	10–42	3–30	− 3.713≠	0.000	HS